Division of Allergy, Pulmonary, and Critical Care Medicine.
Division of Respiratory Care.
Am J Respir Crit Care Med. 2021 Aug 1;204(3):294-302. doi: 10.1164/rccm.202009-3561OC.
Respiratory support (noninvasive ventilation or high-flow nasal cannula) applied at the time of extubation has been reported to reduce reintubation rates, but concerns regarding effectiveness have limited uptake into practice. To determine if providing postextubation respiratory support to all patients undergoing extubation in a medical ICU would decrease the incidence of reintubation. We conducted a pragmatic, two-armed, cluster-crossover trial of adults undergoing extubation from invasive mechanical ventilation between October 1, 2017, and March 31, 2019, in the medical ICU of an academic medical center. Patients were assigned to either protocolized postextubation respiratory support (a respiratory therapist-driven protocol in which patients with suspected hypercapnia received noninvasive ventilation and patients without suspected hypercapnia received high-flow nasal cannula) or usual care (postextubation management at the discretion of treating clinicians). The primary outcome was reintubation within 96 hours of extubation. A total of 751 patients were enrolled. Of the 359 patients assigned to protocolized support, 331 (92.2%) received postextubation respiratory support compared with 66 of 392 patients (16.8%) assigned to usual care, a difference driven by differential use of high-flow nasal cannula (74.7% vs. 2.8%). A total of 57 patients (15.9%) in the protocolized support group experienced reintubation compared with 52 patients (13.3%) in the usual care group (odds ratio, 1.23; 95% confidence interval, 0.82 to 1.84; = 0.32). Among a broad population of critically ill adults undergoing extubation from invasive mechanical ventilation at an academic medical center, protocolized postextubation respiratory support, primarily characterized by an increase in the use of high-flow nasal cannula, did not prevent reintubation compared with usual care.Clinical trial registered with www.clinicaltrials.gov (NCT0328831).
在拔管时应用呼吸支持(无创通气或高流量鼻导管)已被报道可降低再插管率,但对其有效性的担忧限制了其在实践中的应用。本研究旨在确定在接受有创机械通气拔管的重症监护病房(ICU)患者中,对所有患者提供拔管后呼吸支持是否会降低再插管率。这是一项在学术医疗中心的 ICU 中,于 2017 年 10 月 1 日至 2019 年 3 月 31 日期间,对接受有创机械通气拔管的成人进行的实用、双臂、群组交叉试验。患者被分为接受程序化拔管后呼吸支持(根据是否怀疑高碳酸血症,由呼吸治疗师驱动的方案,怀疑高碳酸血症的患者接受无创通气,无怀疑高碳酸血症的患者接受高流量鼻导管)或常规治疗(由主治临床医生决定拔管后的管理)。主要结局为拔管后 96 小时内再插管。共纳入 751 例患者。在接受程序化支持的 359 例患者中,331 例(92.2%)接受了拔管后呼吸支持,而在接受常规治疗的 392 例患者中,66 例(16.8%)接受了常规治疗,这一差异主要是由于高流量鼻导管的使用差异(74.7%比 2.8%)。在接受程序化支持组中,57 例(15.9%)患者经历了再插管,而在接受常规治疗组中,52 例(13.3%)患者经历了再插管(比值比,1.23;95%置信区间,0.82 至 1.84; = 0.32)。在学术医疗中心接受有创机械通气拔管的广泛危重症成人中,与常规治疗相比,程序化拔管后呼吸支持(主要特征是增加使用高流量鼻导管)并不能预防再插管。临床试验注册于 www.clinicaltrials.gov(NCT0328831)。